Neuraxpharm and partner Minoryx Therapeutics, meanwhile, were unable to convince the CHMP that they should get conditional approval for PPAR gamma agonist Nezglyal (leriglitazone) as a treatment ...
The CHMP has issued a positive opinion for the drug as a treatment for adults with insufficiently controlled type 2 diabetes, to improve glycaemic control as an adjunct to diet and exercise ...
Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
A federal judge temporarily blocked Donald Trump's attempt to deport alleged Venezuelan gang members using the Alien Enemies Act of 1798. Trump claimed the Tren de Aragua gang posed a national ...
News-Medical.Net on MSN1d
Novel cyclic peptide antagonist can be a promising therapeutic approach for MASHThe farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Human African ...
Dependency-Track is an intelligent Component Analysis platform that allows organizations to identify and reduce risk in the software supply chain.
12 March 2025 Shares of Danish biotech Zealand Pharma were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback